MYOF (myoferlin) depletion in breast cancer cells has shown to promote mesenchymal to epithelial transformation and stall invasion [22] with potential as a biomarker or drug target for metastatic cancer diagnosis and therapy [28]. Here, MYOF is linked to metastatic malignant neoplasm.